A. Michael Lincoff

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

nejm.org

healio.com Favicon

diabetesjournals.org Favicon

internationaljournalofcardiology.com Favicon

care.diabetesjournals.org

Articles

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial - Nature Medicine

May 13, 2024 | nature.com | Ildiko Lingvay |Eric Barros |Helen M. Colhoun |Cintia Cercato |A. Michael Lincoff |Jorge Plutzky

AbstractIn the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).
Special Collection : Obesity

Apr 6, 2024 | jacc.org | Christopher M. Kramer |Milton Packer |Subodh Verma |A. Michael Lincoff

SUMMIT 2024: A Video Interview With Harlan Krumholz and Milton Packer Obesity Trials Collection at JACC SUMMIT SELECT STEP-HFpEF FLOW A Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity. Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity. Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction.
Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial

Feb 5, 2024 | jamanetwork.com | Shalender Bhasin |A. Michael Lincoff |Steven Nissen

Key PointsQuestion Does testosterone replacement therapy (TRT) prevent progression from prediabetes to diabetes or induce glycemic remission in middle-aged and older men with hypogonadism?
Impact of Bempedoic Acid on Total Cardiovascular Events

Jan 17, 2024 | jamanetwork.com | Stephen Nicholls |Adam Nelson |A. Michael Lincoff |Danielle Brennan

Key PointsQuestion Does bempedoic acid reduce the total burden of cardiovascular events in high-risk patients?
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Nov 11, 2023 | nejm.org | A. Michael Lincoff |Helen M. Colhoun |John Deanfield |Scott Emerson

AbstractSemaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.
Bempedoic Acid for Primary Prevention of Cardiovascular Events-Reply

Nov 7, 2023 | jamanetwork.com | Steven Nissen |Stephen Nicholls |A. Michael Lincoff |Venu Menon

Bempedoic Acid for Primary Prevention of Cardiovascular Events—Reply Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients Steven E. Nissen, MD; Venu Menon, MD; Stephen J. Nicholls, MBBS, PhD; Danielle Brennan, MS; Luke Laffin, MD; Paul Ridker, MD; Kausik K. Ray, MD, MPhil; Denise Mason, BSN; John J. P. Kastelein, MD; Leslie Cho, MD; Peter Libby, MD; Na Li, PhD; JoAnne Foody, MD; Michael J. Louie, MD, MPH, MSc; A.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Mar 11, 2023 | nejm.org | Steven Nissen |A. Michael Lincoff |Danielle Brennan |Denise Mason

AbstractBackgroundBempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. Methods Download a PDF of the Research Summary.